News
Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...
A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...
Despite boasting a new owner, the Indiana manufacturing plant that Novo Nordisk picked up as part of its parent company's ...
These were among the concerns of a recent regulatory inspection of a key, but historically troubled, manufacturing plant that ...
The FDA has identified critical lapses at a production facility operated by Novo Nordisk that is used by several drugmakers, ...
1d
TipRanks on MSNSepterna Begins Phase 1 Trial for SEP-631
The latest announcement is out from Septerna, Inc. ( (SEPN) ).
1d
TipRanks on MSNSepterna doses first participants in Phase 1 trial of SEP-631
Septerna (SEPN) announced the dosing of the first participants in its Phase 1 clinical trial of SEP-631, a selective oral small molecule ...
The pharma giant has almost doubled the size of its workforce over the last five years but is now looking to tighten cost controls amid challenges in the obesity-drug market.
The initiative aims to identify and support new ideas for innovative oral formulations for peptide drugs such as GLP-1 ...
Discover potential risks for Novo Nordisk using Charlie Munger's inversion model. Explore market share, R&D, and why this ...
Wegovy-maker Novo Nordisk has implemented a global hiring freeze covering job roles that are not critical for its business, ...
Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to patients who pay for the medications with cash. Starting this week, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results